RASH
MCID: EXN002
MIFTS: 58

Exanthem (RASH)

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Exanthem

MalaCards integrated aliases for Exanthem:

Name: Exanthem 12 6 15 17
Exanthema 12 44
Rash 12 15
Rashes 42

Classifications:



External Ids:

Disease Ontology 12 DOID:0050486
ICD9CM 34 782.1
MeSH 44 D005076
NCIt 50 C111884
SNOMED-CT 67 112625008
ICD10 32 R21
UMLS 70 C0015230

Summaries for Exanthem

MedlinePlus : 42 A rash is an area of irritated or swollen skin. Many rashes are itchy, red, painful, and irritated. Some rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get rashes. Contact dermatitis is a common type of rash. It causes redness, itching, and sometimes small bumps. You get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. Some rashes develop right away. Others form over several days. Although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. Because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary : Exanthem, also known as exanthema, is related to viral exanthem and severe cutaneous adverse reaction. An important gene associated with Exanthem is SYK (Spleen Associated Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Nevirapine and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and liver, and related phenotypes are Decreased cell viability after pRB stimulation and homeostasis/metabolism

Disease Ontology : 12 A skin disease that is characterized by a rash that results from a variety of causes including bacteria, viruses, toxins, drugs and autoimmune disorders.

Wikipedia : 73 An exanthem is a widespread rash occurring on the outside of the body and usually occurring in children.... more...

Related Diseases for Exanthem

Diseases in the Exanthem family:

Bacterial Exanthem Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1016)
# Related Disease Score Top Affiliating Genes
1 viral exanthem 32.7 TNF CRP CD8A CD4
2 severe cutaneous adverse reaction 32.0 TNF GPT CYP3A4 CTLA4 CRP CD8A
3 measles 31.0 TNF IL6 IL2 IFNA1
4 drug reaction with eosinophilia and systemic symptoms 31.0 TNF CRP
5 covid-19 31.0 TNF IL6 IFNA1 EGFR
6 meningitis 30.9 TNF IL6 IL2 CRP ALB
7 pustulosis of palm and sole 30.9 TNF CRP CCR6
8 drug allergy 30.8 GPT CYP3A4 CRP CD4 ALB
9 vasculitis 30.8 TNF IL6 CTLA4 CRP
10 purpura 30.8 TNF IL6 CRP
11 allergic disease 30.8 TNF SYK IL6 IL2 ICOSLG CTLA4
12 scarlet fever 30.8 TNF CRP ALB
13 pfeiffer syndrome 30.8 IL2 HRAS H2AC18 CD8A CD4 CCR6
14 conjunctivitis 30.7 TNF IL6 IL2
15 contact dermatitis 30.7 TNF IL6 IL2 CD4 CCR6
16 erythema multiforme 30.7 TNF IL6 IL2
17 chickenpox 30.7 TNF IL6 IL2 IFNA1 ICOSLG CTLA4
18 pneumonia 30.7 TNF IL6 CRP ALB
19 mouth disease 30.7 IL6 IFNA1 H2AC18 CRP CCR6
20 erythema nodosum 30.6 TNF IL6 CTLA4 CRP
21 african tick-bite fever 30.6 TNF IL6 GPT
22 lymphadenitis 30.6 TNF ICOSLG CRP CD4 CCR6
23 pharyngitis 30.6 TNF IL6 GPT CRP CD8A CD4
24 erysipelas 30.6 TNF IL6 IL2 CRP
25 allergic contact dermatitis 30.6 TNF IL6 CD4 CCR6
26 psoriasis 30.5 TNF IL6 IL2 CTLA4 CD4 CCR6
27 toxic shock syndrome 30.5 TNF IL6 IL2 EGFR CRP
28 urticaria 30.5 TNF SYK KIT IL6 CRP CD4
29 uveitis 30.5 TNF IL6 IL2 CTLA4
30 severe acute respiratory syndrome 30.4 TNF IL6 IFNA1 CRP
31 stomatitis 30.4 TNF IL6 IL2 IFNA1 CD4
32 secondary syphilis 30.4 CRP CD8A CD4
33 rubella 30.4 TNF IL6 IL2
34 herpes zoster 30.4 TNF IL2 IFNA1 ICOSLG CD8A CD4
35 chlamydia 30.4 TNF IL6 CRP
36 thrombocytopenic purpura, autoimmune 30.4 ICOSLG CD4 CCR6
37 monkeypox 30.4 IFNA1 CD8A CD4
38 ileus 30.4 TNF IL6 CRP
39 parotitis 30.4 CRP CD8A CD4 ALB
40 interstitial nephritis 30.4 ICOSLG CRP CCR6 ALB
41 meningoencephalitis 30.4 TNF IL6 CRP CD8A CD4 CCR6
42 myelitis 30.4 TNF IL6 ICOSLG CCR6
43 rosacea 30.3 TNF IL6 CRP CCR6
44 adult-onset still's disease 30.3 TNF IL6 CRP
45 granulomatous dermatitis 30.3 TNF CD8A CD4
46 dermatitis 30.3 TNF IL6 IL2 CTLA4 CD8A CD4
47 disseminated intravascular coagulation 30.3 TNF IL6 GPT CRP
48 streptococcal toxic-shock syndrome 30.3 TNF IL6 IL2
49 poliomyelitis 30.3 TNF IFNA1 CD8A CD4
50 brucellosis 30.3 TNF IL6 IL2 CRP

Graphical network of the top 20 diseases related to Exanthem:



Diseases related to Exanthem

Symptoms & Phenotypes for Exanthem

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell viability after pRB stimulation GR00230-A-1 8.32 SYK

MGI Mouse Phenotypes related to Exanthem:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 ALB CCR6 CD274 CD4 CRP CTLA4
2 endocrine/exocrine gland MP:0005379 10.26 ALB CD4 CD8A CTLA4 EGFR ERBB2
3 cardiovascular system MP:0005385 10.25 ALB CRP CTLA4 EGFR ERBB2 HRAS
4 immune system MP:0005387 10.25 ALB CCR6 CD274 CD4 CD8A CRP
5 digestive/alimentary MP:0005381 10.19 ALB CD4 CTLA4 EGFR ERBB2 HRAS
6 integument MP:0010771 10.1 CD274 CD4 CD8A CTLA4 EGFR ERBB2
7 liver/biliary system MP:0005370 9.97 ALB CTLA4 EGFR IL2 IL6 KIT
8 neoplasm MP:0002006 9.92 ALB EGFR ERBB2 HRAS IL2 IL6
9 no phenotypic analysis MP:0003012 9.86 CD274 CD4 EGFR HRAS IL2 KIT
10 normal MP:0002873 9.81 ALB CCR6 CD4 CD8A CTLA4 EGFR
11 respiratory system MP:0005388 9.61 CTLA4 EGFR ERBB2 HRAS IL2 IL6
12 skeleton MP:0005390 9.32 CD274 CTLA4 EGFR ERBB2 GPT HRAS

Drugs & Therapeutics for Exanthem

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nevirapine Approved Phase 4 129618-40-2 4463
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Tocopherol Approved, Investigational Phase 4 1406-66-2
6
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
7
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
8
Menthol Approved Phase 4 2216-51-5 16666
9
Allantoin Approved Phase 4 97-59-6 204
10
Pancrelipase Approved, Investigational Phase 4 53608-75-6
11
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
12 Tocotrienol Investigational Phase 4 6829-55-6
13 Vitamin K 1 Phase 4
14 Reverse Transcriptase Inhibitors Phase 4
15 Anti-Retroviral Agents Phase 4
16 Antiviral Agents Phase 4
17 Anti-Infective Agents Phase 4
18 Antiparasitic Agents Phase 4
19 Anti-Bacterial Agents Phase 4
20 Antibiotics, Antitubercular Phase 4
21 Antimalarials Phase 4
22 Antiprotozoal Agents Phase 4
23 Emollients Phase 4
24 glucocorticoids Phase 4
25 Hormone Antagonists Phase 4
26 Anti-Inflammatory Agents Phase 4
27 Antineoplastic Agents, Hormonal Phase 4
28 Liver Extracts Phase 4
29 Aloe Phase 4
30 Tocotrienols Phase 4
31 Tocopherols Phase 4
32 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
33 Sodium-Glucose Transporter 2 Inhibitors Phase 4
34 Hypoglycemic Agents Phase 4
35 Anti-HIV Agents Phase 4
36 pancreatin Phase 4
37
Gefitinib Approved, Investigational Phase 2, Phase 3 184475-35-2 123631
38
Fusidic Acid Approved, Investigational Phase 3 6990-06-3 3000226
39
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 12560
40
Afamelanotide Approved, Investigational Phase 3 75921-69-6
41
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
42
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
43
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
44
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
45
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
46
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
47
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
48
Desloratadine Approved, Investigational Phase 3 100643-71-8 124087
49 Coconut Approved Phase 3
50
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
2 Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
3 A Parallel, Evaluator-Blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Two Marketed Topical Skin Protectants Containing Zinc Oxide in Children With Diaper Rash Completed NCT00219466 Phase 4
4 A Multi-center, Double-blinded Randomized Trial for Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
5 Randomized Controlled Trial Comparing the Efficacy and Safety of Calmoseptine Ointment and Desitin Maximum Strength 40% Zinc Oxide Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Completed NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
6 The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment Completed NCT01318356 Phase 4 Doxycycline;Placebo
7 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Completed NCT04193566 Phase 4 Forxiga
8 A Multicenter, Randomized, Open-label, Controlled Study of Nevirapine (VIRAMUNE®) and a Short Course of Prednisone to Determine the Safety and Effectiveness of This Strategy in Preventing Nevirapine (VIRAMUNE®) Associated Rash. Completed NCT02184299 Phase 4 Nevirapine;Prednisone
9 The Healthy Baby Bottoms Study: A Trial of Theraworx Foam Formulation for the Prevention and Treatment of Diaper Dermatitis Suspended NCT04101890 Phase 4 Diaper care with Theraworx
10 Randomized, Double Blind, Placebo-controlled Trial of Creon in Patients With Low Faecal Pancreatic Elastase Terminated NCT01865695 Phase 4 Creon
11 Pilot Study of Acitretin for Treatment of Erlotinib-induced Skin Rash Withdrawn NCT01299220 Phase 4 Acitretin
12 A Clinical Observation to Assess the Safety and Consumers' Satisfaction of Moussik vs Desitin Creamy Ointment in Prophylaxis of Diaper Rash. A Single Blind, Multicenter, Randomized, Cross-over Study Withdrawn NCT01167465 Phase 4
13 Neotililty Trial: Effect of Coenzyme Q10 on Semen Parameters in Men With Idiopathic Infertility Withdrawn NCT03104998 Phase 4 Coenzyme Q10
14 Gefitinib Alone or With Concomitant Whole Brain Radiotherapy for Patients Harboring an EGFR Mutation With Multiple Brain Metastases From Non-Small-cell Lung Cancer: a Phase II/III Randomized Controlled Trial Unknown status NCT02338011 Phase 2, Phase 3 Gefitinib
15 A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
16 Glucocorticoids Associated With Antihistamines Versus Antihistamines Randomized Double Blinded for the Management of Acute Urticaria in Emergency Completed NCT02565680 Phase 2, Phase 3 placebo;prednisone
17 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Topical Sunscreen to Prevent Erlotinib- or Cetuximab-Induced Skin Rash [or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash] Completed NCT00362986 Phase 3 sunscreen
18 A Randomized Controlled Clinical Study Comparing the Efficacy and Safety of Calmoseptine vs Destin Maximum Strength Diaper Rash Paste in Treatment of Incontinence Associated Dermatitis in Older Children and Adults Completed NCT02080247 Phase 3 Skin care regimen with Calmoseptine ointment;Skin care regimen with Destin ointment
19 A Randomized, Double-blind, Prospective Trial of Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in Non-small Cell Lung Cancer Completed NCT01528488 Phase 2, Phase 3
20 A Randomized, Open Label Study to Compare the Use of the Dermatological Creams Verutex, Eritex and Fisiogel in the Management of Skin Rash Associated With Tarceva Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer. Completed NCT00718315 Phase 3 erlotinib [Tarceva];fusidic acid [Verutex];erythromycin [Eritex];Fisiogel
21 Phase III Randomized Double-Blind Trial of Bepanthen® Cream Versus Cetomacrogol Cream in the Prevention of Papulopustular Eruption in Patients Receiving Epidermal Growth Factor Receptor Inhibitors (EGFRI): BeCet Completed NCT01136005 Phase 3
22 A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE) Completed NCT04704713 Phase 3 Afamelanotide;Placebo
23 A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Acute Cutaneous Rash Terminated NCT01529242 Phase 3 Desloratadine + Prednisolone;Dexchlorpheniramine + Betamethasone
24 Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial Terminated NCT01595893 Phase 3 Oral Vitamin D 3;Miglyol 812 N
25 Protocol Establishment for the Prevention of Lamotrigine-induced Skin Rash in Epilepsy Patients: A Pilot Study Unknown status NCT03220256 Phase 2 Lamotrigine
26 A Phase II Randomized, Double Blind, Placebo Study to Evaluate the Efficacy of Vitamin K1 Cream Treatment Compared to Placebo for the Prevention of Papulo-pustular Rash in Metastatic Colorectal Patients Receiving First Line EGFRI Treatment. Unknown status NCT01763307 Phase 2 RECONVAL CREAM;PLACEBO
27 Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances Unknown status NCT01729481 Phase 2 Gemcitabine;Erlotinib;Oxaliplatin;Folinic Acid;Irinotecan;5-FU
28 An Open-label, Multicenter, Efficacy and Safety Study of 4-month Canakinumab Treatment With 6-month Follow-up in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS). Completed NCT01242813 Phase 2 ACZ885
29 A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy. Completed NCT00886795 Phase 1, Phase 2 abatacept (Orencia ®)
30 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group With a Crossover Confirmation Period Study of RWJ-333369 for the Treatment of Postherpetic Neuralgia. Completed NCT00492323 Phase 2 placebo;carisbamate
31 A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer Completed NCT00473083 Phase 2 Minocycline;Clindamycin 2% in hydrocortisone 1% lotion;Erlotinib;Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
32 A Phase II Randomized Study of OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer (NSCLC) Completed NCT00230126 Phase 2 erlotinib
33 Double Blind Placebo Controlled Trial, for Evaluating Preventive Therapy With Either Oint Threolone Versus Synthomycine Versus Aqua Cream, for EGFR'I Induced Acneiform Rash Completed NCT01256437 Phase 2 Threolone ointment;ointment Synthomycine;Aqua cream
34 Phase II, Open-label, Single Blind, Randomised Clinical Trial With Tetracycline as a Prophylaxis for Rash and Dermatological Recommendations Versus Dermatological Recommendations in Patients With NSCLC Receiving Treatment With BIBW 2992 Completed NCT01880515 Phase 2 Tetracycline
35 Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor Completed NCT03440515 Phase 2 Prednisone
36 The Use of Campath-1H, Tacrolimus, and Sirolimus Followed by Sirolimus Withdrawal in Renal Transplant Patients Completed NCT00078559 Phase 1, Phase 2 Alemtuzumab;Sirolimus;Tacrolimus;Methylprednisolone (or equivalent);Acetaminophen;Diphenhydramine;Trimethoprim (TMP)/Sulfa (Bactrim, Septra);Valgancyclovir;Acyclovir;Pentamidine;Clotrimazole;Nystatin
37 A Safety, Tolerability and Efficacy Study of Doxycycline Topical Foam Administered Topically for Prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects With Cancer Receiving Cetuximab or Panitumumab Completed NCT02239731 Phase 2 FDX104 (4% Doxycycline)
38 A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver Completed NCT00803647 Phase 2 5-FU;oxaliplatin;leucovorin
39 A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC) Completed NCT00589667 Phase 2 Pemetrexed plus Gemcitabine
40 A Phase II, Open-label, Intra-patient Dose-escalation Study of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed Prior Chemotherapy Completed NCT00072631 Phase 2 Tarceva (Trademark) (erlotinib HCl, OSI-774)
41 A Randomized, Open Label Study to Evaluate the Effect of Doxycycline on Tarceva-induced Skin Rash in Patients With Non-small Cell Lung Cancer After Failure of First Line Chemotherapy Completed NCT00531934 Phase 2 Doxycline;erlotinib [Tarceva]
42 A Randomized, Open-label, Dose-escalation to Rash Study to Assess the Effect of Tarceva in Combination With Gemcitabine on Overall Survival in Patients With Metastatic Pancreatic Cancer. Completed NCT00652366 Phase 2 Erlotinib, escalating dose;Erlotinib, standard dose;Gemcitabine
43 A Phase II Trial Assessing Metronidazol Actavis 1% Topical Cream in the Prevention and Treatment of Erlotinib Associated Rash Completed NCT00642473 Phase 2 Erlotinib;Metronidazole Actavis
44 A Multi-Center Study Investigating the Correlation Between TARCEVA ®-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy Completed NCT01174563 Phase 2 erlotinib [Tarceva]
45 An Open Label Study of Tarceva in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas : Relationship Between Skin Rash and Survival Completed NCT00461708 Phase 2 Erlotinib;Gemcitabine
46 A Two-Part, Phase II Randomized Trial to Explore Topical Spironolactone to Prevent/Attenuate Rash From Epidermal Growth Factor Receptor Inhibitors (Panitumumab and Cetuximab) in Advanced Cancer Patients Completed NCT01867294 Phase 2 Doxycycline;Spironolactone;Sunscreen;Therapeutic Hydrocortisone
47 A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab Completed NCT00332163 Phase 2 Irinotecan;FOLFIRI;Pre-emptive Skin Treatment;Reactive Skin Treatment
48 Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label Recruiting NCT03363763 Phase 2 Sirolimus 0.2%;Sirolimus 0.4%;Placebo ointment
49 A Phase II Study of Thiotepa Added to Fludarabine and Melphalan as the Preparative Regime for Alternative Donor Transplantation Recruiting NCT03342196 Phase 2 Melphalan;Thiotepa;Fludarabine;Keratinocyte Growth Factor (KGF)
50 A Randomized, Double-blind, Placebo-controlled Trial of AC-701 for Treatment of Skin Rash in Subjects With EGFR Inhibitor Therapy Recruiting NCT04239846 Phase 2 AC-701 Topical Gel 0.3%

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Genetic Tests for Exanthem

Anatomical Context for Exanthem

MalaCards organs/tissues related to Exanthem:

40
Skin, Breast, Liver, Bone, Myeloid, Heart, Bone Marrow

Publications for Exanthem

Articles related to Exanthem:

(show top 50) (show all 28010)
# Title Authors PMID Year
1
Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives. 42 61
33232965 2021
2
Zika Virus Infection in a Cohort of Pregnant Women with Exanthematic Disease in Manaus, Brazilian Amazon. 42 61
33260784 2020
3
COVID-19 Associated Multisystem Inflammatory Syndrome: A Systematic Review and Meta-analysis. 42
33463127 2020
4
SARS-CoV-2 associated viral encephalitis with mortality outcome. 61
33654659 2021
5
Prediction of post-vaccination Guillain-Barré syndrome using data from a passive surveillance system. 61
33533072 2021
6
Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512). 61
32918131 2021
7
Systemic lupus erythematosus and varicella-like rash following COVID-19 in a previously healthy patient. 61
33527457 2021
8
Dermatological and Molecular Evidence of Human Cercarial Dermatitis in North-Eastern Poland. 61
33566721 2021
9
Adverse reactions to radiopharmaceuticals: liver radiopharmaceuticals. 61
33346605 2021
10
Tick bites in Japan. 61
33586799 2021
11
Pain, swelling and irritability in the sun: what is the diagnosis? 61
31434640 2021
12
Sulfadiazine Hypersensitivity and Desensitization in Children With Congenital Toxoplasmosis: A Report on Two Cases. 61
33181786 2021
13
Staphylococcal enterotoxin B- and lipopolysaccharide-induced toxic shock syndrome in a burn patient. 61
33410193 2021
14
Comparison of Short-Duration and Chronic Premenarchal Vulvar Complaints. 61
33246095 2021
15
Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience. 61
33274825 2021
16
Gianotti-Crosti syndrome: a challenging exanthema. 61
33795277 2021
17
Resolution of huge thrombi in bilateral ventricles caused by severe lupus cardiomyopathy. 61
33497305 2021
18
Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. 61
33405101 2021
19
Necrotizing lymphadenitis : A case report and literature review. 61
33241524 2021
20
Refractory and Fatal Presentation of Severe Autoimmune Hemolytic Anemia in a Child With the DNASE1L3 Mutation Complicated With an Additional DOCK8 Variant. 61
32205782 2021
21
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer. 61
33168656 2021
22
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. 61
33794206 2021
23
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. 61
33168657 2021
24
It's a rash: Antibiotic allergies in the modern era of antibiotic stewardship. 61
33561701 2021
25
Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients. 61
33462734 2021
26
Dermatologic manifestations of COVID-19: a comprehensive systematic review. 61
33141443 2021
27
Three cases diagnosed not Lyme disease but "tick-associated rash illness (TARI)" in Japan. 61
33309106 2021
28
Pediatric Demodicosis Associated with Gain-of-Function Variant in STAT1 Presenting as Rosacea-Type Rash. 61
33404972 2021
29
Vanishing evidence of the non-blanching rash? 61
33186514 2021
30
Visual Diagnosis: Rash and Fatigue in a 6-year-old Girl. 61
33795472 2021
31
Young man with a diffuse rash and red eyes after recovery from COVID-2019. 61
33778806 2021
32
A man with a rash. 61
33763660 2021
33
Reactive infectious mucocutaneous eruption: Mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions. 61
32918499 2021
34
Maculopapular rash and acute breathlessness in a young man. 61
33249598 2021
35
A polymorphic papulosquamous rash with micaceous scales. 61
33747298 2021
36
Kawasaki-like disease and acute myocarditis in the SARS-CoV-2 pandemic - reports of three adolescents. 61
33119481 2021
37
Murine Typhus in 5 Children Hospitalized for Multisystem Inflammatory Syndrome in Children. 61
33431429 2021
38
Rituximab desensitization in pediatric acute lymphoblastic leukemia with severe anaphylaxis. 61
32787558 2021
39
Allopurinol to Prevent Mercaptopurine Adverse Effects in Children and Young Adults With Acute Lymphoblastic Leukemia. 61
33750748 2021
40
Validating clinical practice guidelines for the management of children with non-blanching rashes in the UK (PiC): a prospective, multicentre cohort study. 61
33186517 2021
41
New Adjuvant Drug for Lung Cancer. 61
33755621 2021
42
Clinical features of viral exanthems. 61
33786547 2021
43
Clinical spectrum and outcome of immunoglobulin A vasculitis in children: A 10-year clinical study. 61
33319433 2021
44
Smoking associates with distinct clinical phenotypes in patients with systemic lupus erythematosus: a nationwide Danish cross-sectional study. 61
33811110 2021
45
Immediate reaction to ibrutinib amenable to oral desensitization. 61
33793357 2021
46
Acute monocytic leukemia presenting as generalized lymphadenopathy and skin rash in a toddler: highlighting the clinicopathologic mimics. 61
33095510 2021
47
A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study. 61
33386556 2021
48
Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial. 61
33231925 2021
49
Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. 61
33473176 2021
50
Qingxue jiedu formulation ameliorated DNFB-induced atopic dermatitis by inhibiting STAT3/MAPK/NF-κB signaling pathways. 61
33388430 2021

Variations for Exanthem

ClinVar genetic disease variations for Exanthem:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SYK NM_003177.7(SYK):c.1649C>T (p.Ser550Phe) SNV Pathogenic 989386 GRCh37: 9:93650098-93650098
GRCh38: 9:90887816-90887816
2 SYK NM_003177.7(SYK):c.1649C>A (p.Ser550Tyr) SNV Pathogenic 989389 GRCh37: 9:93650098-93650098
GRCh38: 9:90887816-90887816
3 SYK NM_003177.7(SYK):c.1350G>A (p.Met450Ile) SNV Likely pathogenic 989237 GRCh37: 9:93640021-93640021
GRCh38: 9:90877739-90877739
4 SYK NM_003177.7(SYK):c.1024C>A (p.Pro342Thr) SNV Likely pathogenic 989387 GRCh37: 9:93636974-93636974
GRCh38: 9:90874692-90874692
5 SYK NM_003177.7(SYK):c.1057G>A (p.Ala353Thr) SNV Uncertain significance 989236 GRCh37: 9:93637007-93637007
GRCh38: 9:90874725-90874725

Expression for Exanthem

Search GEO for disease gene expression data for Exanthem.

Pathways for Exanthem

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 TNF SYK KIT IL6 IL2 IFNA1
2
Show member pathways
13.7 TNF KIT IL6 IL2 IFNA1 HRAS
3
Show member pathways
13.57 TNF KIT IL6 IL2 IFNA1 HRAS
4
Show member pathways
13.43 SYK KIT ICOSLG HRAS ERBB2 EGFR
5
Show member pathways
13.38 TNF SYK KIT IL6 IL2 HRAS
6
Show member pathways
13.36 SYK KIT IL6 IL2 HRAS ERBB2
7
Show member pathways
13.32 TNF SYK KIT IL6 IL2 IFNA1
8
Show member pathways
13.31 TNF KIT IL6 IL2 HRAS ERBB2
9
Show member pathways
13.3 TNF KIT IL6 IL2 HRAS ERBB2
10
Show member pathways
13.23 TNF SYK IL6 IL2 IFNA1 HRAS
11
Show member pathways
13.1 SYK KIT IL6 IL2 HRAS EGFR
12
Show member pathways
13.08 SYK KIT IL6 IL2 HRAS EGFR
13
Show member pathways
12.97 TNF SYK IL6 IFNA1 HRAS EGFR
14
Show member pathways
12.92 TNF SYK KIT IL6 IL2 IFNA1
15 12.85 KIT IL6 IL2 IFNA1 HRAS ERBB2
16 12.8 TNF KIT HRAS ERBB2 EGFR
17
Show member pathways
12.8 TNF IL6 IL2 IFNA1 ICOSLG CTLA4
18
Show member pathways
12.76 SYK KIT HRAS ERBB2 EGFR
19
Show member pathways
12.67 TNF SYK IL2 ICOSLG HRAS CD4
20
Show member pathways
12.55 TNF SYK IL2 IFNA1 HRAS
21
Show member pathways
12.55 TNF IL6 IL2 HRAS ERBB2 EGFR
22
Show member pathways
12.45 IL6 IL2 IFNA1 HRAS EGFR
23 12.44 TNF SYK KIT IL2 IFNA1 CTLA4
24
Show member pathways
12.43 KIT IL6 IL2 HRAS ERBB2 EGFR
25
Show member pathways
12.43 SYK IL2 ICOSLG CTLA4 CD4
26 12.38 TNF IL6 IL2 HRAS CD4
27
Show member pathways
12.37 TNF IL6 IL2 CCR6
28
Show member pathways
12.37 TNF IL6 IL2 CRP ALB
29
Show member pathways
12.35 IL6 HRAS ERBB2 EGFR
30 12.33 TNF HRAS ERBB2 EGFR
31
Show member pathways
12.29 TNF KIT IL6 IL2 IFNA1 EGFR
32 12.26 TNF SYK IL6 IFNA1
33
Show member pathways
12.25 TNF IL6 HRAS EGFR
34
Show member pathways
12.24 ICOSLG CTLA4 CD4 CD274
35
Show member pathways
12.24 TNF SYK IL6 IL2 HRAS
36 12.16 SYK KIT ERBB2 EGFR
37 12.16 ICOSLG CTLA4 CD8A CD4 CD274
38 12.09 TNF IL6 IL2 CD8A CD4
39 12.06 TNF IL6 IL2 EGFR
40 11.95 TNF KIT IL6 IL2 CD8A CD4
41 11.92 TNF KIT IL6 CD8A CD4
42
Show member pathways
11.82 TNF IL6 IL2 HRAS EGFR CTLA4
43
Show member pathways
11.81 TNF IL6 IL2 CD4
44 11.78 IL6 IL2 HRAS ERBB2 EGFR
45 11.77 HRAS ERBB2 EGFR
46 11.77 SYK CTLA4 CD8A CD4
47 11.76 KIT HRAS ERBB2 EGFR
48 11.71 IL6 HRAS EGFR
49
Show member pathways
11.69 TNF IL6 IL2
50
Show member pathways
11.68 TNF IL2 CD8A

GO Terms for Exanthem

Cellular components related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 TNF KIT ERBB2 EGFR CTLA4 CD8A
2 cell surface GO:0009986 9.63 TNF KIT EGFR CD4 CD274 CCR6
3 extracellular space GO:0005615 9.61 TNF KIT IL6 IL2 IFNA1 GPT
4 external side of plasma membrane GO:0009897 9.23 TNF KIT ICOSLG CTLA4 CD8A CD4

Biological processes related to Exanthem according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.27 KIT IL6 IFNA1 ICOSLG HRAS ERBB2
2 immune system process GO:0002376 10.12 SYK IL2 ICOSLG CTLA4 CD8A CD4
3 positive regulation of cell proliferation GO:0008284 10.08 KIT IL6 IL2 HRAS ERBB2 EGFR
4 positive regulation of gene expression GO:0010628 10.06 TNF KIT IL6 HRAS ERBB2 CRP
5 cytokine-mediated signaling pathway GO:0019221 9.99 TNF KIT IL6 IL2 IFNA1 CD4
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 TNF HRAS EGFR CD4
7 MAPK cascade GO:0000165 9.97 TNF KIT IL2 HRAS ERBB2 EGFR
8 positive regulation of protein kinase B signaling GO:0051897 9.96 TNF KIT ERBB2 EGFR
9 T cell receptor signaling pathway GO:0050852 9.95 ICOSLG HRAS CTLA4 CD4
10 protein autophosphorylation GO:0046777 9.94 SYK KIT ERBB2 EGFR
11 peptidyl-tyrosine phosphorylation GO:0018108 9.91 SYK KIT ERBB2 EGFR
12 positive regulation of protein phosphorylation GO:0001934 9.88 TNF IL2 HRAS ERBB2 EGFR CD4
13 cell surface receptor signaling pathway GO:0007166 9.87 SYK HRAS ERBB2 EGFR CD8A CD4
14 immune response GO:0006955 9.86 TNF IL6 IL2 CTLA4 CD8A CD4
15 positive regulation of interferon-gamma production GO:0032729 9.85 TNF IL2 HRAS
16 positive regulation of epithelial cell proliferation GO:0050679 9.85 HRAS ERBB2 EGFR
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 TNF KIT IL6 IL2
18 positive regulation of smooth muscle cell proliferation GO:0048661 9.84 TNF IL6 EGFR
19 positive regulation of T cell proliferation GO:0042102 9.84 IL6 IL2 CD4 CD274
20 positive regulation of interleukin-8 production GO:0032757 9.83 TNF SYK IL6
21 humoral immune response GO:0006959 9.83 TNF IL6 IFNA1 CCR6
22 positive regulation of MAPK cascade GO:0043410 9.83 KIT IL6 HRAS ERBB2 CD4
23 T cell costimulation GO:0031295 9.82 ICOSLG CTLA4 CD274
24 T cell activation GO:0042110 9.81 ICOSLG CD8A CD4
25 T cell differentiation GO:0030217 9.8 KIT IL2 CD4
26 positive regulation of interleukin-10 production GO:0032733 9.79 SYK IL6 CD274
27 positive regulation of JAK-STAT cascade GO:0046427 9.77 TNF KIT IL6
28 regulation of ERK1 and ERK2 cascade GO:0070372 9.77 SYK ERBB2 EGFR
29 positive regulation of kinase activity GO:0033674 9.77 KIT IL2 ERBB2 EGFR CD4
30 adaptive immune response GO:0002250 9.76 SYK IL2 IFNA1 ICOSLG CTLA4 CD8A
31 positive regulation of superoxide anion generation GO:0032930 9.73 SYK EGFR CRP
32 vascular endothelial growth factor production GO:0010573 9.66 TNF IL6
33 negative regulation of ERBB signaling pathway GO:1901185 9.65 ERBB2 EGFR
34 negative regulation of lipid storage GO:0010888 9.65 TNF IL6 CRP
35 leukocyte activation involved in immune response GO:0002366 9.63 SYK IL2
36 enzyme linked receptor protein signaling pathway GO:0007167 9.63 SYK ERBB2 CD4
37 positive regulation of MAP kinase activity GO:0043406 9.35 TNF KIT HRAS ERBB2 EGFR
38 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.1 SYK KIT ERBB2 EGFR CD8A CD4

Molecular functions related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 KIT ERBB2 EGFR
2 protein tyrosine kinase activity GO:0004713 8.92 SYK KIT ERBB2 EGFR

Sources for Exanthem

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....